Calibration-aware evaluation of perturbation models shows that deep learning models can outperform baselines.

Lipid nanoparticles are improved by including RNA cargo size in the design process.

The thermostability of RNA vaccines is improved with AI.

A photolabile oligonucleotide system enables spatially resolved single-cell measurements to show how the epigenome regulates gene expression.

Modified nanopore simultaneously identifies diverse biomolecules and their modifications.

Six proteomic clocks are applied in a clinical trial to assess anti-aging effects.

Interpreting transcript diversity requires moving beyond ‘known’ versus ‘novel’ and towards a multidimensional framework based on technical credibility, contextual prevalence, reproducibility, molecular consequence and phenotypic relevance.

While technologies for smaller gene edits, such as base editing, have already entered clinical trials, larger gene cargoes face different challenges, including low editing efficiencies, delivery vehicle size constraints, and possible immunogenicity. Programmable genome engineering systems using recombinases; transposases, including CRISPR-associated transposases (CASTs); genome writing systems; and retrotransposons promise different avenues for therapy, but each system has unique limitations. What are the most promising strategies to further develop these technologies, and which parameters need to be further improved to make them efficient and safe for therapy? We asked three experts in the field to share their thoughts on the challenges and opportunities.

A breast cancer drug linked with a test to detect ESR1 mutations in circulating tumor DNA is one of a wave of new drugs developed to tackle resistance to estrogen-receptor-targeted therapies.

China’s Decree 818 aims to bring hospital-based cell, gene and individualized therapies into the clinic safely. Its success will depend on whether it is consistently applied and whether adverse outcomes are reported, keeping patient safety at the forefront and holding institutions accountable for the results.

Recent patents relating to systems, methods and compositions for use in synthetic biology.